Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002368 · ClinicalTrials.gov registry record · Phase 3
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
A Phase 3 study of HIV Infections, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 20
- Study locations
NCT00002368 is a Phase 3 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,000 participants, above the 442-participant average among 542 other HIV Infections trials with a reported enrollment target (352% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00002368, a Phase 3 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG Nevirapine
Study Locations (20)
California
- Dr G Michael Wool - Los Angeles
- UCLA School of Medicine / Ctr for Research and Education - Los Angeles
- AIDS Research Ctr / Palo Alto VA Health Care System - Palo Alto
- AIDS Community Research Consortium - Redwood City
- ViRx Inc - San Francisco
- San Francisco Gen Hosp / UCSF AIDS Program - San Francisco
- Harbor - UCLA Med Ctr - Torrance
Florida
- Anthony LaMarca - Fort Lauderdale
- North Broward Hosp District - Fort Lauderdale
- Dr Robert Schwartz - Fort Myers
- McGregor Clinic / Lee County Public Health Unit - Fort Myers
- P Andrew Coley - Jacksonville
- Goodgame Med Group - Maitland
- Infectious Disease Research Institute Inc - Tampa
Colorado
- Infectious Disease Specialists - Colorado Springs
- Denver Public Health - Denver
- Dr Miguel Mogyoros / Clinical Research Dept - Denver
Alabama
- Drug Research and Analysis Corp - Montgomery
Delaware
- Wilmington Hosp - Wilmington
District of Columbia
- Novum Inc - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002368
The ClinicalTrials.gov registry entry for NCT00002368 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 442-participant average among 542 other HIV Infections trials with a reported enrollment target (352% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Lamivudine is the first listed.
NCT00002368 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00002368 about?
NCT00002368 is a clinical study titled "The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs". To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
What is the current status of trial NCT00002368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants.
What conditions does trial NCT00002368 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002368?
The interventions under investigation include: Lamivudine (DRUG), Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00002368?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002368 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.